BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24143252)

  • 1. The use of molecular analyses in voided urine for the assessment of patients with hematuria.
    Beukers W; Kandimalla R; van Houwelingen D; Kovacic H; Chin JF; Lingsma HF; Dyrskjot L; Zwarthoff EC
    PLoS One; 2013; 8(10):e77657. PubMed ID: 24143252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.
    van Kessel KE; Beukers W; Lurkin I; Ziel-van der Made A; van der Keur KA; Boormans JL; Dyrskjøt L; Márquez M; Ørntoft TF; Real FX; Segersten U; Malats N; Malmström PU; Van Criekinge W; Zwarthoff EC
    J Urol; 2017 Mar; 197(3 Pt 1):590-595. PubMed ID: 27746284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of an Epigenetic Profile for the Detection of Bladder Cancer in Patients with Hematuria.
    van Kessel KE; Van Neste L; Lurkin I; Zwarthoff EC; Van Criekinge W
    J Urol; 2016 Mar; 195(3):601-7. PubMed ID: 26327355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
    Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
    Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Urine Based Genomic Assay to Triage Patients with Hematuria for Cystoscopy.
    van Kessel KEM; de Jong JJ; Ziel-van der Made ACJ; Roshani H; Haensel SM; Wolterbeek JH; Boevé ER; Oomens EHGM; van Casteren NJ; Krispin M; Boormans JL; Steyerberg EW; van Criekinge W; Zwarthoff EC
    J Urol; 2020 Jul; 204(1):50-57. PubMed ID: 31985322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines.
    de Jong JJ; Pijpers OM; van Kessel KEM; Boormans JL; Van Criekinge W; Zwarthoff EC; Lotan Y
    Eur Urol Oncol; 2023 Apr; 6(2):183-189. PubMed ID: 36089502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: A prospective, single-center study.
    Guo RQ; Xiong GY; Yang KW; Zhang L; He SM; Gong YQ; He Q; Li XY; Wang ZC; Bao ZQ; Li XS; Zhang K; Zhou LQ
    Urol Oncol; 2018 Jul; 36(7):342.e15-342.e23. PubMed ID: 29706459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study.
    Cha EK; Tirsar LA; Schwentner C; Christos PJ; Mian C; Hennenlotter J; Martini T; Stenzl A; Pycha A; Shariat SF; Schmitz-Dräger BJ
    Eur Urol; 2012 Jan; 61(1):185-92. PubMed ID: 21924544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma.
    Kavalieris L; O'Sullivan PJ; Suttie JM; Pownall BK; Gilling PJ; Chemasle C; Darling DG
    BMC Urol; 2015 Mar; 15():23. PubMed ID: 25888331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria.
    Dahmcke CM; Steven KE; Larsen LK; Poulsen AL; Abdul-Al A; Dahl C; Guldberg P
    Eur Urol; 2016 Dec; 70(6):916-919. PubMed ID: 27417036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer.
    Cha EK; Tirsar LA; Schwentner C; Hennenlotter J; Christos PJ; Stenzl A; Mian C; Martini T; Pycha A; Shariat SF; Schmitz-Dräger BJ
    World J Urol; 2012 Dec; 30(6):847-52. PubMed ID: 23124847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
    Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
    BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.
    O'Sullivan P; Sharples K; Dalphin M; Davidson P; Gilling P; Cambridge L; Harvey J; Toro T; Giles N; Luxmanan C; Alves CF; Yoon HS; Hinder V; Masters J; Kennedy-Smith A; Beaven T; Guilford PJ
    J Urol; 2012 Sep; 188(3):741-7. PubMed ID: 22818138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel urine-based DNA methylation biomarkers for urothelial bladder carcinoma detection in patients with hematuria.
    Abol-Elnazer HF; Awadalla A; Ahmed AE; Abol-Enein H; Al Ganzouri MA; Elsawy AA
    Arab J Urol; 2023; 21(4):248-257. PubMed ID: 38178946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
    Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
    BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A noninvasive multianalyte urine-based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria.
    Karnes RJ; Fernandez CA; Shuber AP
    Mayo Clin Proc; 2012 Sep; 87(9):835-42. PubMed ID: 22883743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria.
    Sarosdy MF; Kahn PR; Ziffer MD; Love WR; Barkin J; Abara EO; Jansz K; Bridge JA; Johansson SL; Persons DL; Gibson JS
    J Urol; 2006 Jul; 176(1):44-7. PubMed ID: 16753364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective external validation of a bladder cancer detection model.
    Lotan Y; Svatek RS; Krabbe LM; Xylinas E; Klatte T; Shariat SF
    J Urol; 2014 Nov; 192(5):1343-8. PubMed ID: 24859442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine cell-based DNA methylation classifier for monitoring bladder cancer.
    van der Heijden AG; Mengual L; Ingelmo-Torres M; Lozano JJ; van Rijt-van de Westerlo CCM; Baixauli M; Geavlete B; Moldoveanud C; Ene C; Dinney CP; Czerniak B; Schalken JA; Kiemeney LALM; Ribal MJ; Witjes JA; Alcaraz A
    Clin Epigenetics; 2018; 10():71. PubMed ID: 29854012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of a urine-based tumor marker for screening lower urinary tract in low-risk patients with asymptomatic microscopic hematuria.
    Sagnak L; Ersoy H; Gucuk O; Ozok U; Topaloglu H
    Urol Int; 2011; 87(1):35-41. PubMed ID: 21654152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.